Navigation Links
Quark Pharmaceuticals Expands International Patent Protection for Compounds Targeting the RTP801 Gene
Date:10/26/2009

eting approvals and to generate commercial sales. We are vigilant about upholding our industry leadership position in siRNA R&D by protecting our pipeline with an aggressive and comprehensive approach to intellectual property generation and management. . We are also focused on broadening our intellectual property estate to further protect and enhance the value of our product pipeline."

About the PF-4523655 (RTP801i-14) Clinical Program

PF-4523655 (RTP801i-14) is a synthetic, siRNA molecule designed to inhibit the expression of Quark's proprietary target, RTP801. The product candidate is licensed to Pfizer on an exclusive worldwide basis. Quark discovered RTP801 using its BiFAR(TM) target discovery platform, which identifies clinically relevant genes and proteins that are critical to reversing a given disease phenotype when inhibited. The Company owns a family of patents covering the RTP801 gene and protein sequences, specific antibodies, and gene inhibition across different disease indications.

The ongoing Phase II study is a prospective, randomized, multi-center, dose-ranging study is designed to evaluate the safety and efficacy of PF-4523655 versus laser therapy in 160 patients with DME. In this study, patients are randomized to receive intravitreal injections of one of three dose levels of PF-4523655, or laser therapy. Therapeutic effect will be evaluated by assessing visual acuity and retinal morphology.

About Quark Pharmaceuticals, Inc.

Quark Pharmaceuticals, Inc. is a development-stage pharmaceutical company engaged in discovering and developing novel RNAi-based therapeutics. Quark has a fully integrated drug development platform that spans therapeutic target identification to drug development. Quark's RNAi technology includes novel siRNA structures and chemistry providing Quark with freedom to operate in the siRNA intellectual property arena, as well as the ability for non-invasive delivery
'/>"/>

SOURCE Quark Pharmaceuticals, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3

Related medicine technology :

1. Quark Pharmaceuticals, Inc. Presented Positive Preclinical Results of Systemic RNAi Compound for Acute Renal Failure (ARF)
2. Quark Pharmaceuticals Extends Research Agreement with State University of New York for Proprietary siRNA Compounds for Acute Hearing Loss
3. Quark Pharmaceuticals Files Patent Application Covering Novel Chemical Modifications to its RNAi Molecules
4. Quark Pharmaceuticals Appoints New Chief Medical Officer
5. Quark Pharmaceuticals Signs Collaboration Agreement With University of Michigan for Development of Proprietary SiRNA Compounds for Noise-Induced Hearing Loss
6. Quark Pharmaceuticals, Inc. Announces First Systemic siRNA Dosing in Humans
7. Quark Pharmaceuticals Announces First Patient Dosing by Pfizer in Phase II Trial of RNAi Therapy in Diabetic Macular Edema
8. Silence Therapeutics to Receive $1.9m Milestone Payment as Pfizer and Quark Commence Phase II Trial
9. Quark Pharmaceuticals Announces First RNAi Drug Candidate Having a Novel, Proprietary Structure Covered by Quark Intellectual Property
10. Quark Pharmaceuticals Announces Publication of Study on Use of siRNA against Proprietary Target for Inhibiting Tumor Growth and Sensitization of Cancer Cells to Chemotherapy
11. Quark Pharmaceuticals Announces Dosing of the First Patient in Phase I/II Clinical Trial for Systemically Delivered siRNA Drug Candidate for Delayed Graft Function
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:10/19/2014)... , Deutschland, October 19, 2014 ... CRT-Fallstudien gefragt. Das Problem dabei ist, ... Informationen mit der Kompetenz zu teilen. ... und deshalb freuen wir uns umso mehr, dass ... gebeten, ihre Gepflogenheiten bei Kühlketten aufzuschreiben - mit ...
(Date:10/17/2014)... 17, 2014 With the recent changes ... has come across several challenges in creating and ... globalization.  The Medical Affairs ... to providing benchmarking and best practices across critical ... a service composed of three stages: 1) member-driven ...
(Date:10/17/2014)...  Hanger, Inc. (NYSE: HGR ) announced ... operations for the quarter ended September 30, 2014, on ... conference call to discuss these results is scheduled to ... 2014. Those wishing to participate should call 1-877-662-6095. A ... by dialing 1-855-859-2056 and referencing Conference ID # 91880739. ...
Breaking Medicine Technology:Vergleichsbericht zu Pharma-Kühlketten und CRT 2Early Key Findings from the Medical Affairs Consortium Research 2
... 2011 Carbylan BioSurgery, Inc. announced today the completion ... trial to evaluate the safety and effectiveness of two ... in patients with osteoarthritis of the knee.   Hydros ... combination products. "Hydros and Hydros TA are ...
... MAP Pharmaceuticals, Inc. (Nasdaq: MAPP ) today ... J.P. Morgan Healthcare Conference on Tuesday, January 11, 2011 at ... live webcast of the presentation will be available on the ... . A replay will also be available within 24 hours ...
Cached Medicine Technology:Carbylan BioSurgery Completes Enrollment in Key Clinical Feasibility Study of Hydros and Hydros TA in Patients With Pain From Knee Osteoarthritis; Core Patent Issued 2Carbylan BioSurgery Completes Enrollment in Key Clinical Feasibility Study of Hydros and Hydros TA in Patients With Pain From Knee Osteoarthritis; Core Patent Issued 3
(Date:10/20/2014)... Florida (PRWEB) October 20, 2014 With ... former Gov. Charlie Crist made a brief fundraising stop ... Orlando on Thursday. , Fresh from a debate last ... to take the stage for the first seven minutes ... the former governor described the incident in one word: ...
(Date:10/20/2014)... T.E.N., a technology and information security ... William H. Murray, renowned author and industry visionary, ... Award winner. Presented annually, the ISE® Luminary Leadership ... and industry practitioner for his or her distinguished ... security industry. , Formerly with IBM, Murray is ...
(Date:10/20/2014)... Dunbridge, Ohio (PRWEB) October 20, 2014 ... 50 years, takes pride in manufacturing top-of-the-line absorbent products. ... the image of its most popular brand, Tranquility® Premium ... logo, created a new website, gave its packaging a ... to bring the brand message to the public. , ...
(Date:10/20/2014)... Collins, CO (PRWEB) October 20, 2014 ... dGH assays are the only imaging assays capable ... in a single test.  With these three dimensions ... their ability to detect the widest range of ... translocations—mutations usually missed by other genomic tools, including ...
(Date:10/20/2014)... (PRWEB) October 20, 2014 Punzoné , ... in the U.S., has a lot to celebrate this month. ... country recognizes the achievements and contributions of Americans of Italian ... for Punzoné, and today it shares its favorite Italian cocktails ... trip to Italy - even if it is only in ...
Breaking Medicine News(10 mins):Health News:At Crist Fundraiser, Dan Newlin Says, "No More Robert Germans," Will Seek Changes to Florida Missing Persons Law 2Health News:At Crist Fundraiser, Dan Newlin Says, "No More Robert Germans," Will Seek Changes to Florida Missing Persons Law 3Health News:Bill Murray named 2014 ISE® Luminary Leadership Award Winner 2Health News:Bill Murray named 2014 ISE® Luminary Leadership Award Winner 3Health News:Bill Murray named 2014 ISE® Luminary Leadership Award Winner 4Health News:Tranquility® Premium Protection Incontinence Products Releases New Logo and Website 2Health News:KromaTiD Launches Genome Screening and Discovery Services 2Health News:KromaTiD Launches Genome Screening and Discovery Services 3Health News:Celebrate Italian Heritage Month With Authentic Cocktails from Punzoné: The Only Ultra Premium Line of Organic Imported Italian Vodka 2Health News:Celebrate Italian Heritage Month With Authentic Cocktails from Punzoné: The Only Ultra Premium Line of Organic Imported Italian Vodka 3Health News:Celebrate Italian Heritage Month With Authentic Cocktails from Punzoné: The Only Ultra Premium Line of Organic Imported Italian Vodka 4
... opinion that dairy products provide the necessary dietary calcium ... on collected information available that relates to growth of ... products show little or no relationship between the two., ... to 1500mg of calcium for their bone development. Taking ...
... eating onions may be the key to avoid the risk ... compound in onions, a peptide called GPCS that seems to ... bone cells of newborn mice that were treated with parathyroid ... later exposed to the peptide GPCS. The treatment with the ...
... aureus (MRSA) infection is affecting people// who before had ... interviewing patients with MRSA infections, and reviewing their medical ... are acquired from the community. The rate of being ... below two years old than among those who are ...
... out that excessive exposure to television at the early childhood ... ,A child is considered to be a bully when he ... by actual physical attack on others or by verbal assaults, ... aloud to their children, or provide them with emotional support, ...
... made a study of the genomic sequence of human X ... ,The IOB analysis showed that the human X chromosome ... novel protein-coding regions and 696 known genes. The researchers ... of pseudogenes on X chromosome. The study found 652 pseudogenes ...
... out effective treatment for patients having pain due osteoarthritis in one ... one full Lidoderm patch in the front of the knee and ... study result showed that after six weeks of treatment majority of ... pain relief or more. To the other group the treatment was ...
Cached Medicine News:
... a patented Per-fit™ flexible PVC tube with ... cuff specifically designed to reduce insertion force ... anatomy. The kit s unique obturator/dilator design ... allowing for an easier transition through the ...
... Per-fit™ flexible PVC tube with a tapered ... designed to reduce insertion force and more ... kit s unique obturator/dilator design is engineered ... an easier transition through the tissue into ...
... Self-contained kits provide convenience and cost ... tracheostomy care trays offer a variety of ... and management of the tracheostomized patient. , ... trays, and trays with disposable inner cannula ...
... and cost control. , ,Our full ... variety of wound dressing components for the ... patient. , ,Tray configurations include full ... inner cannula for both rigid and flexible ...
Medicine Products: